Vol. 21/No. 20 | OncologyLive

Panelists Stress Importance of Putting Your Best Foot Forward in Advanced RCC

October 23, 2020


Kidney cancer experts emphasize the importance of risk stratification for guiding treatment decisions and discussed the clinical trials that have shaped the frontline treatment recommendations from the National Comprehensive Cancer Network for advanced clear cell RCC.

Practicing Oncologists Debate New Tactics for Brain Metastases in HER2+ Breast Cancer

October 21, 2020


New approaches for treating patients with HER2-positive metastatic breast cancer are showing signs of efficacy against brain metastases, generating excitement about the potential to make critical advances and sparking questions about optimal sequencing.

Telehealth Is Here to Stay: Opportunities and Challenges for Cancer Care

October 20, 2020

Partner Perspective

Oncology practices across the United States have rapidly increased telehealth use in 2020 to mitigate the risk of coronavirus disease 2019 (COVID-19) to patients with cancer who are at particular risk of complications.

Quad Therapy Induces Deep Responses in Black Patients With Multiple Myeloma

October 16, 2020


Data from a subgroup analysis of the phase 2 GRIFFIN study demonstrated that adding daratumumab to lenalidomide, bortezomib, and dexamethasone improved depth of response, stringent complete response, and minimal residual disease negativity, in Black patients with newly diagnosed multiple myeloma.

Immunotherapy Expert Puts Fresh Focus on AEs

October 15, 2020

In less than 10 years, immune checkpoint inhibitors (ICIs) have dramatically altered the treatment landscape for patients with metastatic melanoma, helping to drive an improvement in 5-year survival rates from historical levels of less than 10% to more than 50% with some regimens.

Complex Clinical Trial Issues Require an Ethical Balancing Act

October 13, 2020

From the Editor

The fundamental objectivity of major scientifically oriented public health agencies has been called into question, while the issue of what constitutes sufficient evidence for a therapeutic strategy to be considered “standard” is also being challenged.